Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

被引：0

作者：

Macarulla, Teresa Mercade

Hubner, Richard

Blanc, Jean-Frederic

Wang-Gillam, Andrea

Li, Chung-Pin

Bodoky, Gyorgy

Dean, Andrew Peter

Yanshen, Shan

Jameson, Gayle S.

Lee, Kyung-Hun

Chiu, Chang-Fang

Schwartsmann, Gilberto

Braiteh, Fadi S.

Cunningham, David

Chen, Li-Tzong

Von Hoff, Daniel D.

Mamlouk, Khalid Kevin

de Jong, Floris A.

Siveke, Jens T.

机构：

[1] Vall d Hebron Univ Hosp, Inst Oncol, Barcelona, Spain

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] CHU Bordeaux, Pole ADEN, Hop Haut Leveque, Bordeaux, France

[4] Washington Univ, Sch Med St Louis, St Louis, MO USA

[5] Taipei Vet Gen Hosp, Taipei, Taiwan

[6] Szent Laszlo Teaching Hosp, Budapest, Hungary

[7] St John God Hosp, Subiaco, WA, Australia

[8] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[9] Honor Hlth, Virginia G Piper Canc Ctr, Scottsdale, AZ USA

[10] Seoul Natl Univ Hosp, Seoul, South Korea

[11] China Med Univ First Hosp, Taichung, Taiwan

[12] Fed Univ, Porto Alegre, RS, Brazil

[13] Comprehens Canc Centers Nevada, Las Vegas, NV USA

[14] Royal Marsden NHS Fdn Trust, London, England

[15] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan

[16] Ipsen Biosci Inc, Cambridge, MA USA

[17] Shire GmbH, Zug, Switzerland

[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期

关键词：

D O I：

10.1200/JCO.2018.36.4_suppl.410

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

410

引用

页数：1

共 49 条

[41] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1
Hubner, R.
Cubillo, A.
Blanc, J-F.
Melisi, D.
von Hoff, D. D.
Wang-Gillam, A.
Chen, L-T.
Becker, C.
Mamlouk, K.
Belanger, B.
Yang, Y.
de Jong, F.
Siveke, J. T.
ANNALS OF ONCOLOGY, 2016, 27
[42] Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
Yoo, Changhoon
Kim, Kyu-Pyo
Kim, Ilhwan
Kang, Myoung Joo
Cheon, Jaekyung
Kang, Byung Woog
Ryu, Hyewon
Jeong, Jae Ho
Lee, Ji Sung
Kim, Kyung Won
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] Multicenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
Yoo, C.
Jeong, J. H.
Kim, K-P.
Cheon, J.
Kim, I.
Kang, M.
Ryu, H.
Kang, B. W.
Ryoo, B-Y.
ANNALS OF ONCOLOGY, 2019, 30
[44] First-line (1L) liposomal irinotecan+5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels
Dean, A.
Bekaii-Saab, T.
Boland, P. M.
Dayyani, F.
Macarulla, T.
Mody, K.
Belanger, B.
Maxwell, F.
Moore, Y.
Wang, T.
Zhang, B.
Wainberg, Z. A.
ANNALS OF ONCOLOGY, 2020, 31 : S941 - S942
[45] Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel
Park, Joon Oh
Kim, Seung Tae
Hong, Jung Yong
Kim, Seong-Jin
Park, Young Suk
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[46] NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Wainberg, Zev A.
Melisi, Davide
Macarulla, Teresa
Pazo-Cid, Roberto
Chandana, Sreenivasa R.
De La Fouchardiere, Christelle
Dean, Andrew Peter
Kiss, Igor
Lee, Woojin
Goetze, Thorsten Oliver
Van Cutsem, Eric
Paulson, Andrew Scott
Bekaii-Saab, Tanios S.
Pant, Shubham
Hubner, Richard
Xiao, Zhimin
Chen, Huanyu
Benzaghou, Fawzi
O'Reilly, Eileen Mary
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA661 - LBA661
[47] NAPOLI-3: A randomized, open-label Phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Goetze, T.
Melisi, D.
Macarulla, T.
Pazo Cid, A. R.
Chandana, R. S.
De La Fouchardiere, C.
Dean, A.
Kiss, I.
Lee, Jin W.
Van Cutsem, E.
Paulson, S.
Bekaii-Saab, T.
Pant, S.
Hubner, R.
Xiao, Z.
Chen, H.
Benzaghou, F.
O'Reilly, E.
Wainberg, A. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 12 - 14
[48] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
Dean, Andrew
Wainberg, Zev A.
Bekaii-Saab, Tanios S.
Hubner, Richard
Macarulla, Teresa
Paulson, Andrew Scott
Cutsem, Eric V.
Maxwell, Fiona
Moore, Yan
Wang, Haofei Tiffany
Zhang, Bin
O'Reilly, Eileen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 202 - 203
[49] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Wainberg, Zev A.
Bekaii-Saab, Tanios S.
Hubner, Richard
Macarulla, Teresa
Paulson, Andrew Scott
Van Cutsem, Eric
Maxwell, Fiona
Moore, Yan
Wang, Haofei Tiffany
Zhang, Bin
O'Reilly, Eileen Mary
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →